Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator MyDogBuster, Dip66, locksflooring, roberteliates, HorseShoe Man, sup105
Search This Board:
Last Post: 10/31/2014 11:01:38 AM - Followers: 590 - Board type: Free - Posts Today: 0
MultiCell Technologies (MCET) 
68 Cumberland Street, Suite 301
Woonsocket, RI 02895
 Office: (401) 762-0045



Ticker - MCET (U.S. Reporting: SEC Filer) 

Estimated outstanding shares: 4.3 Billion a/o October 2014

Estimated Float: 3.97 Billion a/o October 2014

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)



Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development

 MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.

                                       MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.

 MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.

 MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

Therapeutic Candidate  


Discovery Optimization    

Preclinical Development    

Phase 1    

Phase 2/b   

Phase 3    



X X X X  



X X      



X X      



X X      

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc. Corporate Headquarters

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

Find us on Google Maps  

 Management and Board of Directors

Barbara (Corbett) Newmin - Investor Relations

W. Gerald Newmin, Chairman and Chief Executive Officer
Mr. W. Gerald Newmin joined the Company in June 1995.  Mr. Newmin currently serves as Chairman of the Board of Directors and Acting Chief Executive Officer of the Company.  Mr. Newmin is also Chairman and CEO, and a director of Xenogenics Corporation, a majority-owned subsidiary of the Company; Chairman and CEO, and a director of MCT Rhode Island Corp., a wholly-owned subsidiary of the Company; and, CEO and a director of MultiCell Immunotherapeutics, Inc., a majority-owned subsidiary of the Company.  Mr. Newmin has managed NYSE and American Stock Exchange Fortune 500 companies.  Mr. Newmin has been President of Health America Corporation, then the nation’s largest publicly held HMO management company.  Mr. Newmin was Chief Executive Officer and President of The International Silver Company, a diversified multi-national manufacturing company that he restructured.  Mr. Newmin was Chief Operating Officer of numerous Whittaker Corporation operating units, including Production Steel Company, Whittaker Textiles, Bertram Yacht, Trojan Yacht, Columbia Yacht, Narmco Materials and Anson Automotive.  Mr. Newmin was instrumental in Whittaker’s entry into the US and international health care markets.  Mr. Newmin was Western Regional Vice President of American Medicorp, Inc, where he managed 23 acute care hospitals in the Western United States.  Mr. Newmin retired as Chairman and Chief Executive Officer of SYS Technologies, Inc., a high-growth defense technology company in 2003.  Mr. Newmin has a Bachelors degree in Accounting from Michigan State University.

Stephen Chang, PhD (Vice President, Research and Development)
Stephen M. Chang, Ph.D., Director
Dr. Stephen Chang has served as a director of the Company since June 2004.  Dr. Chang has been Chief Scientific Officer (CSO) of Stemgent, Inc. since January 2008.  Prior to joining Stemgent, Dr. Chang served as President and CEO of MultiCell from July 2006 until December 2007, and as President of MultiCell from September 2005 to June 2006.  Prior to joining Multicell, Dr. Chang was the CEO of Astral Immunotherapy which was acquired by Multicell Technologies in September 2005.  Prior to joining Astral, Dr. Chang was CSO and vice president of Canji Inc. / Schering Plough Research Institute in San Diego from 1998 to 2004.  Dr. Chang has also held senior management positions at Chiron and Viagene.  Dr. Chang is currently president of CURES, a coalition of patient advocates, biotechnology companies, pharmaceutical companies, and venture capitalists dedicated to ensuring the safety, research, and development of innovative life saving medications.  Dr. Chang is also a board member of Histogen a privately held company in regenerative medicine.  Dr. Chang earned his doctoral degree in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine.

Grant Miller,  MBA/CFO
Grant Miller, Director
Mr. Miller, appointed to the Board in 2012, received his B.A. from Loma Linda University in Riverside, CA and an MBA in Finance from the University of San Diego, in San Diego, CA. Mr. Miller is Chief Financial & Operating Officer of Sandel Avionics and has served as Chief Financial Officer of Rapid Bridge, LLC, General Manager & Division Controller of Scubapro, Chief Financial Officer of USA Broadband, Inc., Chief Financial Officer & Senior VP Operations of Alitum, and held several positions with WorldXchange and Time Warner Cable, including International Director of Development in Spain and Portugal, Regional Vice President Finance, Corporate Mergers & Acquisitions Analyst, Manager, Finance and Information Systems and Financial Analysis.

Edward Sigmond, Director
Mr. Edward Sigmond has served as a director of the Company since May 2000.  Mr. Sigmond has been in sales, marketing and operations management for the past 20 years.  Mr. Sigmond has served as president of Kestrel Holdings, Inc., a holding company, since its inception in 1997.  Mr. Sigmond served as president of Kestrel Development, a Texas based real estate development company, from 1993 to 1998 when it was dissolved.  Mr. Sigmond studied Marketing and Chemistry at Duquesne University.

Thomas A. Page, Director
Mr. Thomas Page has served as a director of the Company since September 2003.  Mr. Page is Director Emeritus and former Chairman of the Board and CEO of Enova Corporation and San Diego Gas and Electric Company (now part of Sempra Energy).  Prior to the formation of Sempra Energy Corporation as a holding company in 1996, at various times Mr. Page was SDG&E’s chairman, president and CEO and  held one or more of these positions until his retirement in 1998.  Mr. Page joined SDG&E in 1978 as executive vice president and COO.  In 1981, he was elected president and CEO and added the chairmanship in 1983.  Mr. Page has been active in numerous industrial, community and governmental associations and has funded medical research.  He is a director of the San Diego Regional Economic Development Corporation, Community National Bank, Sys Technologies and is an advisory director of Sorrento Ventures.  Mr. Page earned a Bachelor of Science degree in civil engineering, a masters degree in industrial administration and was awarded a doctorate in management, all from Purdue University.  Mr. Page has been licensed as an engineer and as a certified public accountant (CPA).  Mr. Page also serves on the University of California Presidents Council on the National Laboratories.

Scientific Advisors

Alan Tuchman, M.D.
Dr. Tuchman is concurrently in private practice and is Clinical Professor of Neurology at New York Medical College.  He is also the Principal of a healthcare and neuroscience consulting firm.  From 1997 to 2001, Dr. Tuchman was Senior Vice President of Equity Research for Oscar Gruss & Son (Member of the New York Stock Exchange), New York, New York, where he conducted investment research in medical and biotechnology and helped develop marketing strategies for healthcare companies.  Prior to this, he was Vice Dean of Clinical Affairs for New York Medical College where he developed and directed clinical care and medical education policy for 29 affiliated hospitals and served as Professor and Vice Chairman and Program Director for Neurology Residency in the Department of Neurology at the same institution.  At the Lincoln Medical and Mental Health Center, Dr. Tuchman held the positions of Medical Director for the 560-bed hospital from 1990 to 1991 and Director of the Department of Neurology from 1979 to 1994.  Serving in the United States Air Force as Major, he was Chief of Neurology Service for a 16-state region.  Dr. Tuchman earned his B.S. in Chemistry in 1968 from the City College of New York, his M.D. in 1972 from the University of Cincinnati College of Medicine, and his MBA from Columbia University in 1996. He completed his internship at New York Medical College and his residency at the Mount Sinai Hospitals Department of Neurology.  Dr. Tuchman was a clinical fellow in multiple sclerosis at the Albert Einstein College of Medicine Department of Neurology.  Dr. Tuchman is certified by the American Board of Psychiatry and Neurology and the American Society of Neurorehabilitation and is licensed in New York, New Jersey and Ohio.  Dr. Tuchman served as the President of the Epilepsy Society of Southern New York from 1987 1992.



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Quarterly Report (10-q) 10/15/2014 12:34:25 PM
MCET News: MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer 08/25/2014 08:51:00 AM
MCET News: Confidential Treatment Order (ct Order) 08/21/2014 09:53:41 AM
MCET News: Quarterly Report (10-q) 07/15/2014 09:15:45 AM
#38341  Sticky Note For those Who is Long investor and lost sup105 09/08/14 01:57:55 PM
#34376  Sticky Note MultiCell Technologies, Inc. OTCQB TraderpennyX 04/03/14 03:57:31 AM
#27347  Sticky Note PATENT INFORMATION roberteliates 03/28/13 07:50:04 AM
#39002   "mcet still operating and keep going forward ." simon wagstaff 10/31/14 11:01:38 AM
#39001   Simon says, It is all Poop? after sharki 10/31/14 10:58:32 AM
#39000   whatever ths bashers said mcet still operating and gggamm338 10/31/14 10:48:32 AM
#38999   "BS" You are incorrect. Stick with "MCET is curing simon wagstaff 10/31/14 10:44:32 AM
#38998   Everyone know that SW is a lyer . gggamm338 10/31/14 10:43:40 AM
#38997   that's right! don't bother him, he is simon wagstaff 10/31/14 10:35:29 AM
#38996   As the bashers said . Only one guy gggamm338 10/31/14 10:26:27 AM
#38995   BS HorseShoe Man 10/31/14 10:11:32 AM
#38994   Simon is not lying. I can confirm first Dip66 10/31/14 09:26:37 AM
#38993   You have to even lie about this? I simon wagstaff 10/31/14 09:15:49 AM
#38992   No they are not stop lying Simon HorseShoe Man 10/31/14 08:46:37 AM
#38991   Posts are being removed, posters are being banned. simon wagstaff 10/31/14 07:25:37 AM
#38990   BS i have tried to have a professional Dip66 10/30/14 09:37:18 PM
#38989   MCET is not removing any posts the poster is HorseShoe Man 10/30/14 07:12:44 PM
#38988   my Wife has had MS for 25 years bontooth 10/30/14 03:13:40 PM
#38987   The patent on MCT-125 expires in 2019, they simon wagstaff 10/30/14 02:58:39 PM
#38986   Multiple Sclerosis Drugs and Companies Pipeline Review H2.2014. sharki 10/30/14 02:25:30 PM
#38985   You r right , I am on your side . gggamm338 10/30/14 12:31:16 PM
#38984   Facebook is not a place for shareholder questions ztek 10/30/14 12:10:58 PM
#38983   Multismell deleting shareholders comments on their FB page Dip66 10/30/14 11:40:26 AM
#38982   keep dumping multi smell.. Dip66 10/29/14 05:13:24 PM
#38981   Shareholders have lost all respect for this company. Dip66 10/29/14 03:08:58 PM
#38980   No one is buying this pos only mms Turtledip 10/29/14 01:59:55 PM
#38979   Just 100k TheLeo 10/29/14 12:39:33 PM
#38978   So Simon. ...are you still amused by mcet ? mark5050 10/28/14 11:20:44 PM
#38977   this company does a wonderful job leaving shareholders Dip66 10/28/14 10:08:26 PM
#38976   Ok..Thank U wagstaff Decarz 10/28/14 06:45:54 PM
#38975   good post. thanks for update. Dip66 10/28/14 06:30:25 PM
#38974   Understood - Thanks! jjax 10/28/14 04:26:07 PM
#38973   It's not that complicated. Stock options were MyDogBuster 10/28/14 04:18:42 PM
#38972   Hey sorry to not be as educated as jjax 10/28/14 04:03:35 PM
#38971   Mystery solved. MyDogBuster 10/28/14 03:29:13 PM
#38970   "According to Q3 they have 225k...." simon wagstaff 10/28/14 02:40:53 PM
#38969   the moment of truth. Dip66 10/28/14 01:38:00 PM
#38968   According to Q3 they have 225k.... Invest 25k - Decarz 10/28/14 01:29:01 PM
#38967   Decarz - MultiCell already posted on FB recently Dip66 10/28/14 01:06:23 PM
#38966   Good luck with that. simon wagstaff 10/28/14 10:45:55 AM
#38965   When Insiders Does some buying and a BuyBack Decarz 10/28/14 10:35:38 AM
#38964   Isn't STOCK Base Compensation a good thing... For STOCK Decarz 10/28/14 10:33:59 AM
#38963   That's not money to guy the doing the simon wagstaff 10/28/14 10:06:44 AM
#38962   . . At the most recent filing, Simon bontooth 10/28/14 09:56:46 AM
#38961   yeah, look at the most recent filing simon wagstaff 10/28/14 08:29:37 AM
#38960   I don't think that is really what you simon wagstaff 10/28/14 07:42:45 AM
#38959   This is the first time in 6 plus HorseShoe Man 10/28/14 06:35:12 AM
#38958   Loaded today and loading more tomorrow! Thrashing21 10/28/14 12:00:00 AM
#38957   MultiCell just had 225k of profit in Q3 Dip66 10/27/14 11:24:59 PM
#38956   Very clever….sell 21, 000 000 .00 and buy ferenc 10/27/14 03:25:57 PM
#38955   Than coming the R/S and start allover again? ferenc 10/27/14 03:04:44 PM
#38954   700 or so million to go. simon wagstaff 10/27/14 08:56:47 AM
#38953   that's like asking if the rich are done Dip66 10/27/14 08:17:10 AM